NAN-190 

NAN-190 is a serotonin receptor 5-HT antagonist. NAN-190 is a selective antagonist of 5-HT1A. Target: 5-HT in vitro: NAN-190 is a 5-HT1A antagonist. [3] NAN-190 is a selective antagonist of 5-HT1A. [1] in vivo: NAN-190 (0.5 mg/kg, ip), as a 5-HT1A receptor antagonist, is injected concomitantly with the effective dose of fluoxetine. NAN-190 (5-HT1A receptor antagonist) reverses the catalepsy-improving effect of fluoxetine in 6-OHDA lesioned rats. [2]

393.48

C₂₃H₂₇N₃O₃

102392-05-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shahane SA, et al. Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format. J Biomol Screen. 2014 Jan;19(1):66-76.  [Content Brief]

  [2]. Sharifi H, et al. Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors. Adv Pharm Bull. 2013;3(1):203-6.  [Content Brief]

  [3]. Citó MC, et al. Antidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic system. Braz J Med Biol Res. 2015 Jan;48(1):57-64.  [Content Brief]